In this review, the up-to-date understanding of the molecular basis of primary ventricular arrhythmias will be outlined. Two disorders have recently been well described at the molecular level, the long QT syndromes and Brugada syndrome, and in this paper we review the current scientific knowledge of each disease. Curr Opin Cardiol 2000, 15:12- Sudden cardiac death occurs in the United States with a reported incidence of greater than 300,000 persons per year [1••]. Although coronary heart disease is a major cause of death, other causes contribute to this problem. In many of these non-ischemia related cases, autopsies are unrevealing. Interest in identifying the underlying cause of the death in these instances has been focused on cases of unexpected arrhythmogenic death, which is estimated to represent 5% of all sudden deaths. In cases in which no structural heart disease can be identified, the long QT syndrome (LQTS), ventricular preexcitation, and idiopathic ventricular fibrillation or Brugada syndrome [2] (characterized by ST segment elevation in the right precordial leads with or without right bundle branch block [RBBB]) are most commonly considered as likely causes. The purpose of this paper is to describe the current understanding of the clinical and molecular genetic aspects of inherited diseases in which arrhythmias are prominent features, specifically LQTS and Brugada syndrome.
Sudden cardiac death occurs in the United States with a reported incidence of greater than 300,000 persons per year [1••] . Although coronary heart disease is a major cause of death, other causes contribute to this problem. In many of these non-ischemia related cases, autopsies are unrevealing. Interest in identifying the underlying cause of the death in these instances has been focused on cases of unexpected arrhythmogenic death, which is estimated to represent 5% of all sudden deaths. In cases in which no structural heart disease can be identified, the long QT syndrome (LQTS), ventricular preexcitation, and idiopathic ventricular fibrillation or Brugada syndrome [2] (characterized by ST segment elevation in the right precordial leads with or without right bundle branch block [RBBB] ) are most commonly considered as likely causes. The purpose of this paper is to describe the current understanding of the clinical and molecular genetic aspects of inherited diseases in which arrhythmias are prominent features, specifically LQTS and Brugada syndrome.
The long QT syndromes

Clinical description
The LQTSs are inherited or acquired disorders of repolarization identified by the electrocardiographic (ECG) abnormalities of prolongation of the QT interval corrected for heart rate (QT c ) above 460 to 480 ms, relative bradycardia, T-wave abnormalities (Fig. 1) , and episodic ventricular tachyarrhythmias [3] , particularly torsades de pointes (Fig. 2) . The inherited form of LQTS is transmitted as an autosomal dominant or autosomal recessive trait. Acquired LQTS may be seen as a complication of various drug therapies such as macrolide antibiotics (ie, erythromycin), antihistamines (ie, terfenadine), antiarrhythmia agents (ie, quinidine), tricyclic antidepressants, and antifungal agents (ie, ketoconazole). In addition, electrolyte abnormalities such as hypokalemia can result in LQTS. Whether the abnormality is genetically based or acquired, the clinical presentation is similar. In many cases, the initial presentation is syncope, whereas in other instances, recurrent seizures may trigger an evaluation that includes an ECG, leading to the diagnosis. Tragically, some individuals have sudden death as their initial presenting feature and this has been reported to occur in families in some cases.
Clinical genetics
Two differently inherited forms of familial LQTS have been reported. The Romano-Ward syndrome is the most common of the inherited forms of LQTS and appears to be transmitted as an autosomal dominant trait [4, 5] . In this disorder, the disease gene is transmitted to 50% of the offspring of an affected individual. However, low penetrance has been described and therefore gene carriers may, in fact, have no clinical features of disease [6••]. Individuals with Romano-Ward syndrome have the pure syndrome of prolonged QT interval on ECG with the associated symptom complex of syncope, sudden death, and in some patients, seizures [7, 8] Analysis of the predicted amino acid sequence of KVLQT1 suggests that it encodes a potassium channel α-subunit with a conserved potassium-selective poresignature sequence flanked by six membrane-spanning segments similar to shaker-type channels (Fig. 4) . [28, 29, 31] . A putative voltage sensor is found in the fourth membrane-spanning domain (S4) and the selective pore loop is between the fifth and sixth membrane-spanning domains (S5,S6). Biophysical characterization of the KVLQT1 protein confirmed that KVLQT1 is a voltage-gated potassium channel protein subunit that requires coassembly with a β-subunit called minK to function properly (Fig. 4) [28, 29] . Expression of either KVLQT1 or minK alone results in inefficient (or no) current development. When minK and KVLQT1 are coexpressed in either mammalian cell lines or Xenopus oocytes, however, the slowly activating potassium current (I Ks ) is developed in cardiac myocytes [28, 29] . Combination of normal and mutant KVLQT1 subunits forms abnormal I Ks channels and these mutations are believed to act through a dominant-negative mechanism (the mutant form of KVLQT1 interferes with the function of the normal wild-type form through a "poison pill"-type mechanism) or a [41] reported a single-basepair deletion and a stop codon mutation in HERG, confirming this to be LQT2. Currently, this gene is thought to be the second most common gene mutated in LQTS (second to KVLQT1). As with KVLQT1, "private" mutations that are scattered throughout the entire gene without clustering preferentially are seen.
The HERG gene consists of 16 exons and spans 55 kb of genomic sequence [40] . The predicted topology of HERG is shown in Figure 5 and is similar to KVLQT1. Unlike KVLQT1, HERG has extensive intracellular amino-and carboxyl-termini, with a region in the carboxyl-terminal domain having sequence similarity to nucleotide binding domains.
Electrophysiologic and biophysical characterization of expressed HERG in Xenopus oocytes established that HERG encodes the rapidly activating delayed-rectifier potassium current I Kr [42, 43] . Electrophysiologic studies of LQTS-associated mutations showed that they act through either a loss-of-function or a dominant-negative mechanism [44] . In addition, protein trafficking abnormalities have been shown to occur [45, 46] . This channel has been shown to coassemble with β-subunits for normal function, similar to that seen in I Ks. McDonald et al. [47] initially suggested that the complexing of HERG with minK is needed to regulate the I Kr potassium current. Bianchi et al. [48] provided confirmatory evidence that minK is involved in regulation of both I Ks and I Kr . Recently, Abbott et al. [30••] identified MiRP1 as a β-subunit for HERG (see "MiRP1: the LQT6 gene").
SCN5A: the LQT3 gene
The positional candidate gene approach was also used to establish that the gene responsible for chromosome 3-linked LQTS (LQT3) is the cardiac sodium channel gene SCN5A [49, 50] . SCN5A is highly expressed in human myocardium, but not in skeletal muscle, liver, or uterus [51, 52] . Recently, it has been found to be expressed in brain [53] . It consists of 28 exons that span 80 kb and encodes a protein of 2016 amino acids with a putative structure that consists of four homologous domains (DI to DIV), each of which contains six membrane-spanning segments (S1 to S6) similar to the structure of the potassium channel α-subunits (Fig. 6) [41] [42] [43] . Linkage studies with LQT3 families and SCN5A initially demonstrated linkage to the LQT3 locus on chromosome 3p21-24 [51, 52] and three mutations, one 9-basepair intragenic deletion (DK 1505 P 1506 Q 1507 ), and two missense mutations (R 1644 H and N 1325 S), were also identified in six LQTS families [51, 52] . All three mutations were expressed in Xenopus oocytes and it was found that all mutations generated a late phase of inactivation-resistant, mexiletine-and tetrodotoxin-sensitive whole-cell currents through multiple mechanisms [54, 55] . Two of the three mutations showed dispersed reopening after the initial transient, but the other mutation showed both dispersed reopening and long-lasting bursts [55] . These results suggested that SCN5A mutations act through a gain-of-function mechanism (the mutant channel functions normally, but with altered properties such as delayed inactivation) and that the mechanism of chromosome 3-linked LQTS is persistent noninactivated sodium current in the plateau phase of the action potential. Later, An et al. [56] showed that not all mutations in SCN5A are associated with persistent current and demonstrated that SCN5A interacted with β-subunits. Furthermore, mutations in SCN5A have been shown to result in widely different clinical phenotypes. Novel mutations in SCN5A were identified by our laboratory in patients with Brugada syndrome and idiopathic ventricular fibrillation [57••] , disorders with normal QT c but ST segment elevation in the right precordial leads. Electrophysiologically, these mutations result in more rapid recovery from inactivation of the mutant channels or loss of function, causing the Brugada syndrome-type phenotype. defective LQTS was also created [60] . The functional consequences of these mutations include delayed cardiac repolarization and, hence, an increased risk of arrhythmias. (Fig. 4) . MiRP1 is a 123-amino-acid channel protein with a single predicted transmembrane segment similar to that described for minK [58] . Chromosomal localization studies mapped this KCNE2 gene to chromosome 21q22.1, within 79 kb of KCNE1 (minK) and arrayed in opposite orientation [30••] . The open reading frames of these two genes share 34% identity and both are contained in a single exon, suggesting that they are related through gene duplication and divergent evolution.
MiRP1
Three missense mutations associated with LQTS and ventricular fibrillation were identified in KCNE2 by Abbott et al. [30••] , and biophysical analysis demonstrated that these mutants form channels that open slowly and close rapidly, thus diminishing potassium currents. In one case, the missense mutation, a C-to-G transversion at nucleotide 25 that produced a glutamine (Q) to glutamic acid (E) substitution at codon 9 (Q9E) in the putative extracellular domain of MiRP1, led to the development of torsades de pointes and ventricular fibrillation after intravenous clarithromycin infusion (ie, drug induced).
Therefore, like minK, this channel protein acts as a β-subunit but, by itself, leads to risk of ventricular arrhythmia when mutated. These similar channel proteins (ie, minK and MiRP1) suggest that a family of channels exist that regulate ion channel α-subunits. The specific role of this subunit and its stoichiometry remain unclear and are currently being hotly debated.
Genetics and physiology of autosomal recessive long QT syndrome (Jervell and Lange-Nielsen syndrome)
Neyroud et al. [61] reported the first molecular abnormality in patients with JLNS when they reported on two families in which three children were affected by JLNS and in whom a novel homozygous deletion-insertion mutation of KVLQT1 in three patients was found. A deletion of 7 bp and an insertion of 8 bp at the same location led to premature termination at the C-terminal end of the KVLQT1 channel. At the same time, Splawski et al. [62] identified a homozygous insertion of a single nucleotide that caused a frameshift in the coding sequence after the second putative transmembrane domain (S2) of KVLQT1. Together, these data strongly suggested that at least one form of JLNS is caused by homozygous mutations in KVLQT1. This has been confirmed by others [34,63••,64].
As a general rule, heterozygous mutations in KVLQT1 cause Romano-Ward syndrome (LQTS only), whereas homozygous (or compound heterozygous) mutations in KVLQT1 cause JLNS (LQTS and deafness). The hypothetical explanation suggests that although heterozygous KVLQT1 mutations act by a dominant-negative mechanism, some functional KVLQT1 potassium channels still exist in the stria vascularis of the inner ear. Therefore congenital deafness is averted in patients with heterozygous KVLQT1 mutations. For patients with homozygous KVLQT1 mutations, no functional KVLQT1 potassium channels can be formed. It has been shown by in situ hybridization that KVLQT1 is expressed in the inner ear [61] , suggesting that homozygous KVLQT1 mutations can cause the dysfunction of potassium secretion in the inner ear and lead to deafness. However, it should be noted that incomplete penetrance exists and not all heterozygous or homozygous mutations follow this rule [7, 19] .
As with Romano-Ward syndrome, if KVLQT1 mutations can cause the phenotype, it could be expected that minK mutations could also be causative of the phenotype (JLNS). Schulze-Bahr et al. [65] , in fact, showed that mutations in minK result in JLNS syndrome as well, and this was confirmed subsequently [62] . Hence, abnormal I K s current, whether it occurs due to homozygous or compound heterozygous mutations in KVLQT1 or minK, results in LQTS and deafness.
Genotype-phenotype correlations
Moss et al. [66] showed several years ago that the ECG manifestations of LQTS were in great part determined by the channel mutated. Different T-wave patterns were clearly evident when comparing tracings from patients with mutations in LQT1, LQT2, and LQT3. More recently, Zareba et al. [67] showed that the mutated gene may result in a specific clinical phenotype with different triggers and may predict outcome. For instance, these authors suggested that mutations in LQT1 and LQT2 result in early symptoms (ie, syncope) but the risk of sudden death was relatively low for any event. In contrast, mutations in LQT3 resulted in a paucity of symptoms but when symptoms occurred they were associated with a high likelihood of sudden death. In addition, mutations in LQT1 and LQT2 appeared to be associated with stress-induced symptoms, including response to auditory triggers (ie, alarm clock). LQT3, on the other hand, appeared to be associated with sleepassociated symptoms. Coupled with the findings by Moss et al. [66] , it could be suggested that understand-ing the underlying cause of LQTS in any individual could be used to improve survival.
Genetic testing
As described, six LQTS-causing genes have been identified and more than 100 mutations have been described to date. This genetic heterogeneity makes genetic testing more difficult than if a single gene were responsible for the disease. In large families in which linkage analysis may be performed, identification of the gene of interest (if the linkage is to one of the known genes) can be accomplished relatively rapidly and screening of mutations undertaken. Once a mutation is identified in one affected family member (usually the proband), focused screening of the remaining family members for this mutation can be undertaken. In small families or sporadic cases, analysis is much more difficult because mutation screening for all known genes must be initiated. In our laboratory, KVLQT1 (LQT1) mutations are screened initially because this appears to be the most common disease-causing gene [68] . If no mutation is uncovered in KVLQT1, HERG (the next most common gene mutated) is screened before SCN5A, KCNE1, and KCNE2 [30••,33, 51, 69] . If no mutation is found in any of these genes, however, it cannot be concluded that the individual does not have LQTS because other diseasecausing genes remain to be discovered.
Other causes of sudden cardiac death in individuals with structurally normal hearts have been studied as well [70] [71] [72] . In many instances, the underlying cause is never identified. However, one cause of syncope and sudden death, the Brugada syndrome, has recently been intensively studied [2].
Brugada syndrome
Clinical aspects
The first identification of the ECG pattern of RBBB with ST elevation in leads V 1 to V 3 was reported by Osher and Wolff [73] . Shortly thereafter, Edeiken [74] identified persistent ST elevation without RBBB in 10 asymptomatic men, and Levine et al. [75] described ST elevation in the right-sided chest leads and conduction block in the right ventricle in patients with severe hyperkalemia. The first association of this ECG pattern with sudden death was described by Martini et al. [76] and later by Aihara et al. [77] . This association was further confirmed in 1991 by Brugada and Brugada [78] , who described four patients with sudden and aborted sudden death with ECGs demonstrating RBBB and persistent ST elevation in leads V 1 to V 3 . In 1992, these authors characterized what they believed to be a distinct clinical and ECG syndrome [2] .
The finding of ST elevation in the right-sided chest leads has been observed in a variety of clinical and experimental settings and is not unique or diagnostic of Brugada syndrome by itself. Situations in which these ECG findings occur include electrolyte or metabolic disorders, pulmonary or inflammatory diseases, and abnormalities of the central or peripheral nervous system. In the absence of these abnormalities, the term idiopathic ST elevation is often used and may identify Brugada syndrome patients.
The ECG findings and associated sudden and unexpected death have been reported as common problems in Japan and Southeast Asia, where the syndrome most commonly affects men during sleep [79] . This disorder, known as sudden and unexpected death syndrome (SUDS) or sudden unexpected nocturnal death syndrome (SUNDS), has many names in Southeast Asia, including bangungut (to rise and moan in sleep) in the Philippines; non-laitai (sleep-death) in Laos; lai-tai (died during sleep in Thailand; and pokkuri (sudden and unexpectedly ceased phenomenon) in Japan. Generally, SUDS victims are young, healthy men in whom death occurs suddenly with a groan, usually during sleep late at night. No precipitating factors are identified and autopsy findings are generally negative [80] . Life-threatening ventricular tachyarrhythmias as a primary cause of SUDS have been demonstrated, with ventricular fibrillation occurring in most cases [81] .
Brugada syndrome and arrhythmogenic right ventricular dysplasia
Controversy exists concerning the possible association of Brugada syndrome and arrhythmogenic right ventricular dysplasia (ARVD), with some investigators arguing that these are the same disorder or that at least one is a forme fruste of the other [82] [83] [84] [85] [86] [87] . However, the classic echocardiographic, angiographic, and magnetic resonance imaging findings of ARVD are not seen in Brugada syndrome patients. In addition, Brugada syndrome patients typically are without the histopathologic findings of ARVD. Further, the morphology of ventricular tachycardia/ventricular fibrillation differs [88] .
Clinical genetics
Like ARVD, most of the families thus far identified with Brugada syndrome apparently have autosomal dominant inheritance [84,88,89,90••] . In these families, approximately 50% of offspring of affected patients develop the disease. Although the number of families reported has been small, it is likely that this is due to underrecognition as well as premature and unexpected death [90••,91] .
Molecular genetics
In animal studies, blockade of the calcium-independent 4-aminopyridine-sensitive transient outward potassium current (I to ) results in surface ECG findings of elevated, downsloping ST segments [91, 92] due to greater abbrevi-ation in the epicardial action potential compared with the endocardium (which lacks a plateau phase) [93] . Loss of the action potential plateau (or dome) in the epicardium but not endocardium would be expected to cause ST segment elevation and, because loss of the dome is caused by an outward shift in the balance of currents active at the end of phase 1 of the action potential (principally I to and I Ca ), autonomic neurotransmitters such as acetylcholine facilitate loss of the action potential dome by suppressing calcium current and augmenting potassium current, whereas β-adrenergic agonists (ie, isoproterenol, dobutamine) restore the dome by augmenting I Ca [94] [95] [96] . Sodium channel blockers also facilitate loss of the canine right ventricular action potential dome as a result of a negative shift in the voltage at which phase 1 begins [97, 98] . Based on this information, candidate genes (I to , I Ca , and I Na ) could be selected for study.
In 1998, our laboratory reported the findings on six families and several sporadic cases of Brugada syndrome [57••] . The families were initially studied by linkage analysis using markers to the known ARVD loci and linkage was excluded. Candidate gene screening using the mutation analysis approach of single-strand conformation polymorphism analysis and DNA sequencing was performed and SCN5A was chosen for study, based on the suggestions of Gussak and Antzelevitch [ [96] , and Krishnan and Antzelevitch [97, 98] . In three families, mutations in SCN5A were identified [57••] including a missense mutation (C-to-T base substitution) causing a substitution of a highly conserved threonine by methionine at codon 1620 (T1620M) in the extracellular loop between transmembrane segments S3 and S4 of domain IV (DIVS3 to DIVS4), an area important for coupling of channel activation to fast inactivation; a two-nucleotide insertion (AA) that disrupts the splicedonor sequence of intron 7 of SCN5A; and a singlenucleotide deletion (A) at codon 1397 that results in an inframe stop codon that eliminates DIIIS6, DIVS1 to DIVS6, and the carboxyterminus of SCN5A (Fig. 6 ).
Biophysical analysis of the mutants in Xenopus oocytes demonstrated a reduction in the number of functional sodium channels in both the splicing mutation and onenucleotide deletion mutation, which should promote development of reentrant arrhythmias. In the missense mutation, sodium channels recover from inactivation more rapidly than normal. In this case, the presence of both normal and mutant channels in the same tissue would promote heterogeneity of the refractory period, a wellestablished mechanism of arrhythmogenesis. Inhibition of the sodium channel I Na current causes heterogeneous loss of the action potential dome in the right ventricular epicardium, leading to a marked dispersion of depolarization and refractoriness, an ideal substrate for development of reentrant arrhythmias. Phase 2 reentry produced by the same substrate is believed to provide the premature beat necessary for initiation of the ventricular tachycardia and ventricular fibrillation responsible for symptoms in these patients. Interestingly, however, Kambouris et al. [99] identified a mutation in essentially the same region of SCN5A as the T1620M mutation (R1623H), but the clinical and biophysical features of this mutation were found to be consistent with LQT3 and not Brugada syndrome. Hence, there clearly remains a gap in our understanding of these entities.
Conclusions
Ion channel abnormalities result in cardiac arrhythmias that define LQTS and Brugada syndrome. This consistent type of protein alteration causing ventricular arrhythmias supports our concept of a "final common pathway" of cardiovascular disease [100,101••] . In this instance, it appears that ion channelopathies result in ventricular arrhythmias. A similar view of other cardiac disorders can also be considered. For instance, alterations in sarcomeric proteins have been shown to result in hypertrophic cardiomyopathy whereas altered cytoskeletal proteins have been shown to cause dilated cardiomyopathy. It is possible that definition of these "common pathways" can lead to a better understanding of a variety of diseases, as it has for LQTS and Brugada syndrome, and can ultimately lead to better therapies and improved longevity. 
